Vz I have in your column here some ugly ducklings-- ARE YOU OUT OF ALL OF THESE BUY RECOMMENDATIONS? SFWL $8---> $6.25 PZZA $78--> $72 SNAP $10.60---> $9.60 SNAP $10 calls expired worthless. SIRI $3.69--> $3.69 LRN $42----->$42 Let me start over with some of your good ideas. Back In ABB? ASRT-! This was the last call of yours I really liked. any others?
Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up Zacks Equity Research Tue, May 16, 2023, 7:44 AM EDT In this article: KOD Kodiak Sciences KOD reported first-quarter 2023 loss per share of $1.35, wider than the Zacks Consensus Estimate of a loss of $1.28. The company reported a loss of $1.83 per share in the year-ago quarter. The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues. Despite missing earnings estimate, shares of Kodiak jumped 12.6% on Monday due to strong pipeline progress. Kodiak expects to file a single biological license application (BLA) for tarcocimab in the four major retinal vascular disease indications. In the past year, shares of KOD have plunged 13.7% compared with the industry’s 6.1% fall.
GBA Presents: House of Gummy-! | Elite Trader I didn't realize you started the new thread, Stoney. I knew it was coming, but this is for the others that might not be aware. I'm 39 pages behind already.........yeesh!
Let me give u my 2 cents on ASRT-- -> This stock really moved when you recommended it I'm going to say high $5's --> to now. --> I came away from a CC extremely impressed with the frankness of the CEO --> I think Price targets should be around $10? --> It is under priced now. --> There is a reason. These guys are buying Spectrum a stk I know well. As far as I know they are in the process of completing this deal. And shareholders were concerned that ASRT had overpaid... Understandable. What they are buying from SSPI--> Rolvedon There had been concerns Rolvedon sales would not grow fast enough to warrant the valuation Assertio is paying. --> Those concerns were prety much put to bed when SSPI reported 54% sequential growth in Rolvedon sales. So we should close this deal and the stk should elevate.
At the time of the purchase /// Assertio picks up Spectrum and approved drug in $248M- ... Apr 25, 2023 — The deal is worth approximately $248 million. Spectrum's investors will also be eligible for a payout of up to $43 million